Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Jan. 12, 2012

FDA Is Reckless in Its Failure to Remove Dangerous Medical Device From the Market

Stryker Medical’s Wingspan Stent System Comes With High Risk of Stroke or Death, Should Be Recalled

WASHINGTON, D.C. –The Food and Drug Administration’s (FDA) failure to remove from the market a medical device that is supposed to prevent strokes in patients who are at high risk of such events because of severely narrowed brain blood vessels represents a reckless disregard for patient safety, Public Citizen said in an addendum to a petition it sent the agency in December.

Since the December petition, the manufacturer of the Wingspan Stent System – Stryker – and an FDA official have made public statements implying that the continued failure of the FDA to remove this dangerous medical device from the market is related to some alleged lack of comparability between the subjects in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study – the only randomized, controlled study ever done to evaluate the safety and effectiveness of the device – and the patients for whom the Wingspan Stent System was intended to treat under FDA’s 2005 approval of the humanitarian device exemption (HDE) for this device.

The former study, funded by the National Institutes of Health and published in September 2011 in the New England Journal of Medicine, found a 2.5-fold higher risk of suffering a stroke or dying within the first 30 days in patients who had the device implanted than those who received medical treatment alone. Enrollment in the study was stopped in April 2011 – earlier than anticipated – because of these serious safety problems and a lack of evidence that the device provided any benefit.

“The Wingspan Stent System was thought to be too dangerous to implant in any more subjects in the SAMMPRIS trial, and it is likewise too dangerous to use in the hundreds of patients who have clinical characteristics similar to those of the SAMMPRIS trial subjects and the population of patients eligible for treatment with this device under the FDA-approved HDE indication,” said Dr. Michael Carome, deputy director of Public Citizen’s Health Research Group and author of the petition. “Due to the FDA’s unconscionable decision to delay withdrawal of the agency’s approval of the Wingspan Stent System HDE, the continued use of this device exposes patients to an unacceptable risk of serious harm, including death.”  

“Given the evidence of significant harm with no evidence of any benefit, there is no justification for any additional patients to be treated with this dangerous device,” Carome added. “The only way that further use of the device can effectively and definitively be prevented is to immediately remove the device from the market, as it clearly cannot be said to provide reasonable assurance of safety. Rather, it guarantees an unreasonable risk of harm. To allow any further implantation of this device would be highly unethical as well as a violation of FDA laws and regulations.”


Public Citizen is a national, nonprofit consumer advocacy organization based in Washington, D.C. For more information, please visit www.citizen.org.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.